Drug Trial Radar · NCT02607904
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
Last checked: Nov 19, 2026Latest source record: Dec 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Dec 15, 2016
Primary completion
May 27, 2019
Study completion May 27, 2019
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.
Conditions
- Epilepsy
Interventions
GWP42003-PDrug
Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experienced an adverse event.Time frame: Up to 48 weeks.
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
SEIN - Epilepsy Institute in the Netherlands Foundation
Zwolle, Netherlands
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Ruber Internacional
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Sahlgrenska University Hospital
Gothenburg, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.